Clinical trial · Interventional
Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation
NCT04798898CI-TRIAL-00083362ISCOLIMrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To examine radio frequency ablation as a treatment supplement to stimulate immunogenicity and improve survival for patients undergoing curative-intent surgery for colorectal liver metastases.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Metastasis Colon Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| RFA (radiofrequency ablation) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention (+RFA) arm
- description
- Preoperative partial RFA necrosis in the liver metastasis followed by liver resection
- interventionNames
- Device: RFA (radiofrequency ablation)
- type
- NO_INTERVENTION
- label
- Control (-RFA) arm
- description
- Liver resection
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 3 years
- description
- Median survival in each arm
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with colorectal liver metastases planned for resection * At least one tumor size \>=3cm * Performance status 0-1 Exclusion Criteria: * Liver cirrhosis * Extrahepatic metastases that can not be addressed curatively * Other malignant diseases within 5 years prior to diagnosis * Prior RFA treatment
References
Publications (0)
Data not yet available
No reference posted for this study.